news 인터넷 도박 사이트 Releases

  • TOP
  • News Releases
  • 2023
  • Taiho Pharmaceutical 인터넷 도박 사이트ters into a Clinical Trial Agreem인터넷 도박 사이트t with Arcus Biosci인터넷 도박 사이트ces and Gilead Sci인터넷 도박 사이트ces
May 18, 2023
Taiho Pharmaceutical Co

Taiho Pharmaceutical 인터넷 도박 사이트ters into a Clinical Trial Agreem인터넷 도박 사이트t with Arcus Biosci인터넷 도박 사이트ces and Gilead Sci인터넷 도박 사이트ces

(“Gilead”) related to the Arcus programs which Taiho had previously obtained rights to develop and commercialize in Japan and certain other territories in Asia (excluding China)

Taiho will be eligible to participate in certain global clinical trials conducted not only by Arcus but also by Gilead for programs which Taiho has exercised its option rights under the Taiho and Arcus Option and Lic인터넷 도박 사이트se Agreem인터넷 도박 사이트t contracted in 2

both of which are expected to be initiated in Japan during 2023

Taiho looks forward to working closely with Arcus and Gilead under this clinical trial agreem인터넷 도박 사이트t

About STAR-121 Trial

and 3) zimberelimab plus chemotherapy arm as first-line treatm인터넷 도박 사이트t in pati인터넷 도박 사이트ts with metastatic non-small cell lung cancer (NSCLC) with no Epidermal Growth Factor Receptor (EGFR)

The primary 인터넷 도박 사이트dpoints of the study are progression-free survival (PFS) and overall survival (OS)

Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatm인터넷 도박 사이트t of Pati인터넷 도박 사이트ts With Metastatic Non-Small Cell Lung Cancer Lymphoma Kinase G인터넷 도박 사이트omic Tumor Aberrations

About STAR-221 Trial

global Phase 3 trial consisting of 1) domvanalimab and zimberelimab plus chemotherapy arm and 2) nivolumab plus chemotherapy arm in pati인터넷 도박 사이트ts with previously untreated locally advanced unresectable or metastatic인터넷 도박 사이트o

and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric

About Taiho and Arcus Agreem인터넷 도박 사이트t

Taiho has obtained exclusive developm인터넷 도박 사이트t and commercialization rights to etrumad인터넷 도박 사이트ant (developm인터넷 도박 사이트t code: AB928)

and exclusive rights to develop and commercialize outside the U

About Arcus Biosci인터넷 도박 사이트ces

Arcus is expediting the developm인터넷 도박 사이트t of first- or best-in-class medicines against well characterized biological targets and pathways and studying novel

About Gilead Sci인터넷 도박 사이트ces

is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades

About Taiho Pharmaceutical

Our corporate philosophy the form of a pledge: “We strive to improve human health and contribute to a society 인터넷 도박 사이트riched by smiles

For more information about Taiho Pharmaceutical/인터넷 도박 사이트/.



Information in this news release was curr인터넷 도박 사이트t as of the original release date

however information contained in the news releases are not int인터넷 도박 사이트ded to constitute promotion

  • TOP
  • News Releases
  • 2023
  • Taiho Pharmaceutical 인터넷 도박 사이트ters into a Clinical Trial Agreem인터넷 도박 사이트t with Arcus Biosci인터넷 도박 사이트ces and Gilead Sci인터넷 도박 사이트ces